NanoFlu / NVX-CoV2373 quadrivalent vaccine is a combination of two Novavax vaccines, influenza and COVID-19. The latter was created on the basis of an inactivated (killed) virus, the S-protein SARS-CoV-2, presented in the form of recombinant nanoparticles. According to the results of the second and third phases of clinical trials, its effectiveness was 89.3%.
In preclinical studies of the new vaccine, ferrets and hamsters produced high levels of antibodies against both diseases, which increased two weeks after the introduction of the first component of the drug. In the control group, animals received NanoFlu or NVX-CoV2373 vaccines separately. According to the test results, it turned out that the immune response was comparable in all groups.
In a study of the combination vaccine, hamsters were infected with SARS-CoV-2. After they were euthanized, scientists analyzed samples of animal lungs and found no traces of coronavirus there.
The company said that clinical trials of the vaccine in humans are planned for the end of 2021.
“Despite the low incidence of influenza during the COVID-19 pandemic, it remains a significant global public health risk, and the need for universal and more effective vaccines is more important than ever. This combination vaccine has the potential to be an important tool in the long-term fight against both respiratory infections in the future, ”said Gregory M. Glenn, President of Research and Development Novavax.
Note that the development of combined vaccines against coronavirus and influenza is also underway in Russia. The Institute for Experimental Medicine is developing a bivalent vaccine against SARS-CoV-2 and using the live influenza vaccine platform. According to scientists, it will be an intranasal preparation in the form of a spray, which will provide the formation of an immune response on the mucous membrane of the upper respiratory tract. This type of vaccination is considered very gentle, especially for young children.
In turn, the Vector Research Center is developing a combined vaccine against SARS-Cov-2 and influenza based on the measles virus.